CA3049445A1 - Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment - Google Patents

Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment Download PDF

Info

Publication number
CA3049445A1
CA3049445A1 CA3049445A CA3049445A CA3049445A1 CA 3049445 A1 CA3049445 A1 CA 3049445A1 CA 3049445 A CA3049445 A CA 3049445A CA 3049445 A CA3049445 A CA 3049445A CA 3049445 A1 CA3049445 A1 CA 3049445A1
Authority
CA
Canada
Prior art keywords
protein
agent
antibody
cells
lag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3049445A
Other languages
English (en)
French (fr)
Inventor
Thomas Gajewski
Jason Williams
Brendan HORTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of CA3049445A1 publication Critical patent/CA3049445A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
CA3049445A 2017-01-17 2018-01-17 Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment Pending CA3049445A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447199P 2017-01-17 2017-01-17
US62/447,199 2017-01-17
PCT/US2018/014008 WO2018186924A1 (en) 2017-01-17 2018-01-17 Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment

Publications (1)

Publication Number Publication Date
CA3049445A1 true CA3049445A1 (en) 2018-10-11

Family

ID=63712313

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049445A Pending CA3049445A1 (en) 2017-01-17 2018-01-17 Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment

Country Status (6)

Country Link
US (3) US11566077B2 (enExample)
EP (1) EP3570887A4 (enExample)
JP (2) JP2020505342A (enExample)
CN (1) CN110740748A (enExample)
CA (1) CA3049445A1 (enExample)
WO (1) WO2018186924A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114720691A (zh) * 2022-05-10 2022-07-08 广州诺诚生物技术研发有限公司 一种检测生物标志物的试剂盒及其制备方法和应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
US20220023342A1 (en) * 2018-11-30 2022-01-27 Institut Gustave Roussy Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
WO2020146772A1 (en) * 2019-01-11 2020-07-16 The Johns Hopkins University Neuritin regulation of t cell anergy and t regulatory cell function
CN109913414A (zh) * 2019-03-21 2019-06-21 吉林省银丰生物工程技术有限公司 肝癌afp特异性人工抗原递呈细胞诱导试剂盒
US20210130438A1 (en) * 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
CA3164578A1 (en) * 2020-01-14 2021-07-22 Scott KANNER Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases
MX2022011409A (es) * 2020-03-17 2022-12-02 Ohio State Innovation Foundation Vesiculas extracelulares de diseño para tratar la excitotoxicidad.
CN111781358A (zh) * 2020-07-13 2020-10-16 张瑜 Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物
CN112481375B (zh) * 2020-08-27 2024-02-20 江苏大学 一种胃癌标志物及其应用
CN114350616A (zh) * 2022-01-24 2022-04-15 深圳市先康达生命科学有限公司 一种免疫细胞及其制备方法和应用
CN114814231B (zh) * 2022-03-08 2024-08-27 上海交通大学医学院附属瑞金医院 维甲酸诱导基因i在癌症治疗中的应用
CN114561389A (zh) * 2022-03-15 2022-05-31 南通市肿瘤医院 Vrk1表达抑制剂及其应用
CN115631857B (zh) * 2022-04-01 2023-06-23 洛兮医疗科技(杭州)有限公司 甲状腺癌cd8+t细胞免疫相关基因预后预测模型
CN115449548A (zh) * 2022-09-20 2022-12-09 南京鼓楼医院 Stac2卵丘细胞在评估卵母细胞受精能力中的应用
CN116904309A (zh) * 2023-05-26 2023-10-20 西安天隆科技有限公司 能平衡样本管接收部传热差异的模块、方法及pcr装置
CN117192127B (zh) * 2023-08-18 2024-06-14 肇庆医学高等专科学校 一种hcc治疗靶点的发现方法
CN117590001A (zh) * 2023-11-22 2024-02-23 厦门大学 外泌体tmem176b在制备诊断肿瘤的药物中的用途
CN119120385B (zh) * 2024-11-14 2025-03-14 四川大学华西医院 一种具有长效抑瘤效果的嵌合抗原受体t细胞及其制备方法和用途
CN121046325B (zh) * 2025-11-03 2026-03-17 杭州克斯珀基因技术有限公司 增强肿瘤微环境适应性的cep20敲除型til的制备方法及应用
CN121114292B (zh) * 2025-11-13 2026-01-23 合肥谱佳医学检验实验室有限公司 体外定量检测人血清中四种神经酰胺化合物的检测试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA877772B (en) 1986-10-23 1988-04-20 Amoco Corporation Target and background capture methods and apparatus for affinity assays
US20070072209A1 (en) 2005-07-07 2007-03-29 Ashlee Moses Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases
WO2008133641A2 (en) * 2006-10-11 2008-11-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
US8637084B2 (en) * 2009-07-14 2014-01-28 Asahi Kasei Medical Co., Ltd. Treatment method for epithelial cancerous organism
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
CN103221428B (zh) * 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
US9297813B2 (en) * 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2014144666A2 (en) * 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
EP3686219A1 (en) * 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
CA2963935A1 (en) * 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
JP6647315B2 (ja) * 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
EP3471539A4 (en) 2016-06-03 2020-02-26 The Brigham and Women's Hospital KLRG1 SIGNALING THERAPY

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114720691A (zh) * 2022-05-10 2022-07-08 广州诺诚生物技术研发有限公司 一种检测生物标志物的试剂盒及其制备方法和应用
CN114720691B (zh) * 2022-05-10 2022-12-09 深圳粒影生物科技有限公司 一种检测生物标志物的试剂盒及其制备方法和应用

Also Published As

Publication number Publication date
US11566077B2 (en) 2023-01-31
CN110740748A (zh) 2020-01-31
US20200010557A1 (en) 2020-01-09
JP2020505342A (ja) 2020-02-20
WO2018186924A1 (en) 2018-10-11
US20250011452A1 (en) 2025-01-09
US20230416389A1 (en) 2023-12-28
EP3570887A4 (en) 2020-11-25
JP2022184862A (ja) 2022-12-13
EP3570887A1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
US20250011452A1 (en) Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment
US12049643B2 (en) Methods and compositions for modulating cytotoxic lymphocyte activity
US20210172020A1 (en) Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20220170097A1 (en) Car t cell transcriptional atlas
US20210071139A1 (en) Identifying Epigenetic And Transcriptional Targets To Prevent And Reverse T Cell Exhaustion
US11946936B2 (en) Beta-catenin inhibitors in cancer immunotherapy
US20240043934A1 (en) Pancreatic ductal adenocarcinoma signatures and uses thereof
US20240261333A1 (en) Novel targets for enhancing anti-tumor immunity
US11793787B2 (en) Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
WO2021092436A1 (en) Identification of splicing-derived antigens for treating cancer
US20240182518A1 (en) Compositions and methods comprising splicing-derived antigens for treating cancer
CN115697356A (zh) 通过抑制carm1治疗癌症的方法
WO2024158777A1 (en) Methods and compositions for inhibiting suppression of anti-tumor immunity by targeting ligand-receptor interactions present in the placenta
US20260048106A1 (en) Immunotherapy targeting tumor transposable element derivedneoantigenic peptides in glioblastoma
RU2841244C2 (ru) Химерные антигенные рецепторы и пути их применения
Williams et al. c19) United States c12) Patent Application Publication
HK1237869B (en) Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
HK1237869A1 (en) Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

EEER Examination request

Effective date: 20220920

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241218

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241218

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250410